Combined antiangiogenic and immune therapy of prostate cancer

Angiogenesis

Volumn 8, Issue 1, 2005, Pages 13-23

  Huang, Xiaojun ^a   Raskovalova, Tatiana ^a   Lokshin, Anna ^a   Krasinskas, Alyssa ^a   Devlin, Jason ^b   Watkins, Simon ^b   Wolf, Stanley F ^c   Gorelik, Elieser ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c PFIZER INC   (United States)

Author keywords

B7.2 IgG; Combined antiangiogenic and immune therapy; RM1 prostate tumor; SU6668

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT PROTEIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TUMOR CELL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INDOLES; MALE; MICE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRROLES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

MURINAE;

EID: 24044510151     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-005-2893-y     Document Type: Article

References (34)

1. R Kerbel J. Folkman 2002 Clinical translation of angiogenesis inhibitors Nat Rev Cancer 2 727 39
2. D. Sulitzeanu 1993 Immunosuppressive factors in human cancer Adv Cancer Res 60 247 67
3. L Gorelik RA Flavell 2002 Transforming growth factor-beta in T-cell biology Nat Rev Immunol 2 46 53
4. DH Munn AL. Mellor 2004 IDO and tolerance to tumors Trends Mol Med 10 15 8
5. OV Volpert T Fong AE Koch 1998 Inhibition of angiogenesis by interleukin 4 J Exp Med 188 1039 46
6. EE Voest BM Kenyon MS O'Reilly 1995 Inhibition of angio- genesis in vivo by interleukin 12 J Natl Cancer Inst 87 581 6
7. AL Angiolillo C Sgadari DD Taub 1995 Interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo J Exp Med 182 155 62
8. DI Gabrilovich HL Chen KR Girgis 1996 Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat Med 2 1096 103
9. JE Ohm DP. Carbone 2001 VEGF as a mediator of tumor-associated immunodeficiency Immunol Res 23 263 72
10. M Li X Huang Z Zhu 2002 The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors In Vivo 16 577 82
11. M Li X Huang Z Zhu 2001 Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin J Immunother 24 472 81
12. X Huang MK Wong H Yi 2002 Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein Cancer Res 62 5727 35
13. AD Laird P Vajkoczy LK Shawver Cherrington 2000 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res 60 4152 60
14. N. Ferrara 1999 Role of vascular endothelial growth factor in the regulation of angiogenesis Kidney Int 56 794 814
15. C Sundberg M Ljungstrom G Lindmark 1993 Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma Am J Pathol 143 1377 88
16. RM Shaheen WW Tseng DW Davis 2001 Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms Cancer Res 61 1464 8
17. RM Shaheen DW Davis W Liu 1999 Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis Cancer Res 59 5412 6
18. R Erber A Thurnher AD Katsen 2004 Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 338 40
19. K Sturmhoefel K Lee GS Gray 1999 Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant Cancer Res 59 4964 72
20. RC Fields K Shimizu JJ. Mule 1998 Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo Proc Natl Acad Sci USA 95 9482 7
21. + TCR-transgenic T cells J Immunol 161 5268 75
22. PA Baley K Yoshida W Qian 1995 Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer J Steroid Biochem Mol Biol 52 403 13
23. RA Blades PJ Keating LJ McWilliam 1995 Loss of HLA class I expression in prostate cancer: implications for immunotherapy Urology 46 681 6
24. JJ. Mule 2000 Tumor vaccine strategies that employ dendritic cells and tumor lysates: Experimental and clinical studies Immunol Invest 29 127 9
25. K Runyon K Lee K Zuberek 2001 The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses Blood 97 2420 6
26. H Zhou M Sequeira ME Goad 2001 Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy Clin Immunol 101 303 14
27. J. Folkman 1997 Angiogenesis and angiogenesis inhibition: An overview Exs 79 1 8
28. F Mor FJ Quintana IR. Cohen 2004 Angiogenesis-inflammation cross-talk: Vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization J Immunol 172 4618 23
29. + T cells and dependence on IL-4 production J Immunol 172 1347 54
30. JE Ohm DI Gabrilovich GD Sempowski 2003 VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression Blood 101 4878 86
31. HN Lode T Moehler R Xiang 1999 Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases Proc Natl Acad Sci USA 96 1591 6
32. T Boon LJ. Old 1997 Cancer tumor antigens Curr Opin Immunol 9 681 3
33. SA Rosenberg JC Yang DJ Schwartzentruber 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 7
34. SA Rosenberg JC Yang PF Robbins 2003 Cell transfer therapy for cancer: Lessons from sequential treatments of a patient with metastatic melanoma J Immunother 26 385 93